Want to see PAHC full AI Analyst Report?
Net Sales by Segment
Details revenue split across the company’s reporting segments so investors can see which parts of the business contribute most to sales growth and which are more exposed to cyclical demand, input costs, or pricing pressure.Animal Health has become the clear growth engine, with a recent step‑up fueled by new MFA, vaccines and nutritional specialties—management raised guidance on that strength. Mineral Nutrition delivers steady top‑line gains but shows margin compression, so revenue growth isn’t translating into equivalent profit expansion. Performance Products is a meaningful underperformer and could pressure consolidated EBITDA if declines persist. Key risks: Brazil’s regulatory change (virginiamycin), FX/interest cost swings and inventory build; liquidity and upgraded guidance, though, lend credibility to near‑term momentum.
Date | Animal Health | Mineral Nutrition | Performance Products |
|---|---|---|---|
Jun 30, 2026 | $297.60M | $77.00M | $22.20M |
Mar 31, 2026 | $291.23M | $73.42M | $18.90M |
Dec 31, 2025 | $289.98M | $68.94M | $14.99M |
Sep 30, 2025 | $283.46M | $62.99M | $17.45M |
Jun 30, 2025 | $292.48M | $64.15M | $22.07M |
Mar 31, 2025 | $258.38M | $66.77M | $22.67M |
Dec 31, 2024 | $229.42M | $63.25M | $16.59M |
Sep 30, 2024 | $182.52M | $59.06M | $18.85M |
Jun 30, 2024 | $191.51M | $62.06M | $19.59M |
Mar 31, 2024 | $181.33M | $64.23M | $17.66M |